Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background The unbiased amyloid, tau, and neurodegeneration (A/T/N) classification is designed to characterize individuals in the Alzheimer continuum and is currently little explored in clinical cohorts. Objective A retrospective comparison of the A/T/N classification system with the results of a two-year clinical study, with extended follow-up up to 10 years after inclusion. Methods Patients (n = 102) clinically diagnosed as Alzheimer's disease (AD) with dementia or amnestic mild cognitive impairment (MCI), and 61 cognitively healthy control individuals were included.

What this study adds

Evidence grade: Low

The record lists 102 participants. This study retrospectively applied the amyloid, tau, and neurodegeneration (A/T/N) classification to a clinical cohort with long-term follow-up. It compares a classification system with clinical outcomes, not a treatment, cure, or prevention for Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Grøntvedt, G. R., Lauridsen, C., Berge, G., White, L. R., Ø, S., Bråthen, G., et al. (2020). The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-191227

Vancouver

Grøntvedt GR, Lauridsen C, Berge G, White LR, Ø S, Bråthen G, et al. The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up. Journal of Alzheimer's disease : JAD. 2020. doi:10.3233/jad-191227. PMID: 32116257.

BibTeX

@article{grontvedt2020-32116257,
  author  = {Grøntvedt, G. R. and Lauridsen, C. and Berge, G. and White, L. R. and Ø, Salvesen and Bråthen, G. and Sando, S. B.},
  title   = {{The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2020},
  doi     = {10.3233/jad-191227},
  pmid    = {32116257},
  url     = {https://doi.org/10.3233/jad-191227}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This study retrospectively applied the amyloid, tau, and neurodegeneration (A/T/N) classification to a clinical cohort with long-term follow-up. It compares a classification system with clinical outcomes, not a treatment, cure, or prevention for Alzheimer's disease.

Study details

How this study scored 48/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 48 of 100.48 of 100 points earned52 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD)
Journal's citation record 2 / 4 Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 2 / 4 102 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 56 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.0 citations a year over 8 year(s) since 2020
Impact for its field and year 3 / 6 Cited 5.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 5 other studies in this library
Still being cited 2 / 4 Cited 22 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Sigrid Botne Sando: h-index 40 (OpenAlex, whole career)
Institution's track record 1 / 3 Norwegian University of Science and Technology: institution h-index 785 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 32116257)
Free to read 2 / 2 Free to read
Total 48 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →